Email updates

Keep up to date with the latest news and content from BMC Urology and BioMed Central.

Open Access Case report

Adult clear cell sarcoma of the kidney: A case report

Ali R Kural1*, Bulent Onal1, Hamdi Ozkara1, Cansel Cakarir2, Inci Ayan3 and Fulya Y Agaoglu4

Author Affiliations

1 Department of Urology, University of Istanbul, Cerrahpasa School of Medicine, Istanbul, Turkey

2 Department of Pathology, University of Istanbul, Cerrahpasa School of Medicine, Istanbul, Turkey

3 Division of Pediatric Oncology, University of Istanbul, Institute of Oncology, Istanbul, Turkey

4 Department of Radiation Oncology, University of Istanbul, Istanbul School of Medicine, Istanbul, Turkey

For all author emails, please log on.

BMC Urology 2006, 6:11  doi:10.1186/1471-2490-6-11

Published: 3 April 2006

Abstract

Background

Clear cell sarcoma of the kidney (CCSK) in adults is extremely rare. Optimal treatment of adult patients with CCSK remains unclear.

Case presentation

A 22-year-old man presented with a 2-month history of left flank pain. A color duplex sonography revealed a hypervascular, heterogeneous renal mass. Abdominal and pelvic computerized tomography showed a heterogeneous mass originating from the lower pole of the left kidney and infiltrating to the psoas muscle. Further evaluation including bone scan did not demonstrate any evidence of metastases. A left radical nephrectomy with hilar lymphadenectomy through an intraperitoneal approach with an anterior subcostal incision was performed. The histopathological diagnosis of the mass was a clear cell sarcoma of the kidney. No lymph node metastases were found. Concomitant chemo-radiotherapy was performed. Therapy-related serious side effects were not observed. There was no evidence of local recurrence or metastases during the following twenty-four months after therapy.

Conclusion

We believe that the combination therapy is efficacious for preventing the local recurrence and distant metastases. Accurate diagnosis is very important and therapy must also include doxorubicin regardless of the disease stage in adult patients with CCSK.